NASDAQ:RVPH

Reviva Pharmaceuticals Q2 2025 Earnings Results & Report

Reviva Pharmaceuticals logo
$0.34 +0.05 (+17.96%)
As of 11/20/2026 03:57 PM Eastern

Reviva Pharmaceuticals beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$2.40 versus the -$3.00 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Reviva Pharmaceuticals EPS Results

Actual EPS
-$2.40
Consensus EPS
-$3.00
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Q2 2025 Earnings FAQ

Reviva Pharmaceuticals (NASDAQ:RVPH) reported earnings of -$2.40 per share for Q2 2025, beating the consensus estimate of -$3.00. The report was announced on Thursday, August 14, 2025.

Reviva Pharmaceuticals Earnings Headlines

RVPH: FDA Feedback on New Formulation Imminent
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing treatments for disorders involving the central nervous system, respiratory system and inflammation. The company is headquartered in Cupertino, California, and was founded in 2006.

Its lead drug candidate, brilaroxazine (also known as RP5063), is an investigational compound being developed for schizophrenia and other neuropsychiatric conditions. Reviva has also described potential applications for the candidate in respiratory and other disorders. Brilaroxazine is not an approved or marketed medicine.

Reviva’s work centers on research and clinical development of its drug candidates; the company does not currently offer commercial pharmaceutical products.

View Reviva Pharmaceuticals Profile